ID   TRI33_HUMAN             Reviewed;        1127 AA.
AC   Q9UPN9; O95855; Q5TG72; Q5TG73; Q5TG74; Q9C017; Q9UJ79;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 3.
DT   12-OCT-2022, entry version 208.
DE   RecName: Full=E3 ubiquitin-protein ligase TRIM33;
DE            EC=2.3.2.27;
DE   AltName: Full=Ectodermin homolog;
DE   AltName: Full=RET-fused gene 7 protein;
DE            Short=Protein Rfg7;
DE   AltName: Full=RING-type E3 ubiquitin transferase TRIM33 {ECO:0000305};
DE   AltName: Full=Transcription intermediary factor 1-gamma;
DE            Short=TIF1-gamma;
DE   AltName: Full=Tripartite motif-containing protein 33;
GN   Name=TRIM33; Synonyms=KIAA1113, RFG7, TIF1G;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA), FUNCTION, SUBUNIT, AND VARIANT
RP   THR-840.
RX   PubMed=10022127; DOI=10.1038/sj.onc.1202655;
RA   Venturini L., You J., Stadler M., Galien R., Lallemand V., Koken M.H.M.,
RA   Mattei M.-G., Ganser A., Chambon P., Losson R., De The H.;
RT   "TIF1gamma, a novel member of the transcriptional intermediary factor 1
RT   family.";
RL   Oncogene 18:1209-1217(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND BETA), AND VARIANT THR-840.
RX   PubMed=11331580; DOI=10.1093/emboj/20.9.2140;
RA   Reymond A., Meroni G., Fantozzi A., Merla G., Cairo S., Luzi L.,
RA   Riganelli D., Zanaria E., Messali S., Cainarca S., Guffanti A., Minucci S.,
RA   Pelicci P.G., Ballabio A.;
RT   "The tripartite motif family identifies cell compartments.";
RL   EMBO J. 20:2140-2151(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA), AND VARIANT
RP   THR-840.
RC   TISSUE=Brain;
RX   PubMed=10470851; DOI=10.1093/dnares/6.3.197;
RA   Kikuno R., Nagase T., Ishikawa K., Hirosawa M., Miyajima N., Tanaka A.,
RA   Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIV. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:197-205(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 76-1127 (ISOFORMS ALPHA AND BETA),
RP   CHROMOSOMAL TRANSLOCATION WITH RET, AND VARIANT THR-840.
RC   TISSUE=Thyroid;
RX   PubMed=10439047; DOI=10.1038/sj.onc.1202824;
RA   Klugbauer S., Rabes H.M.;
RT   "The transcription coactivator HTIF1 and a related protein are fused to the
RT   RET receptor tyrosine kinase in childhood papillary thyroid carcinomas.";
RL   Oncogene 18:4388-4393(1999).
RN   [6]
RP   SUBUNIT.
RX   PubMed=12096914; DOI=10.1016/s0022-2836(02)00477-1;
RA   Peng H., Feldman I., Rauscher F.J. III;
RT   "Hetero-oligomerization among the TIF family of RBCC/TRIM domain-containing
RT   nuclear cofactors: a potential mechanism for regulating the switch between
RT   coactivation and corepression.";
RL   J. Mol. Biol. 320:629-644(2002).
RN   [7]
RP   FUNCTION AS AN E3 UBIQUITIN-PROTEIN LIGASE, UBIQUITINATION OF SMAD4,
RP   INTERACTION WITH SMAD4, MUTAGENESIS OF CYS-125 AND CYS-128, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=15820681; DOI=10.1016/j.cell.2005.01.033;
RA   Dupont S., Zacchigna L., Cordenonsi M., Soligo S., Adorno M., Rugge M.,
RA   Piccolo S.;
RT   "Germ-layer specification and control of cell growth by Ectodermin, a Smad4
RT   ubiquitin ligase.";
RL   Cell 121:87-99(2005).
RN   [8]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH SMAD2 AND SMAD3, INTERACTION
RP   WITH SMAD2 AND SMAD3, AND SUBCELLULAR LOCATION.
RX   PubMed=16751102; DOI=10.1016/j.cell.2006.03.045;
RA   He W., Dorn D.C., Erdjument-Bromage H., Tempst P., Moore M.A., Massague J.;
RT   "Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the
RT   TGFbeta pathway.";
RL   Cell 125:929-941(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-862; THR-1102 AND SER-1105,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH SMAD2 AND SMAD4.
RX   PubMed=19135894; DOI=10.1016/j.cell.2008.10.051;
RA   Dupont S., Mamidi A., Cordenonsi M., Montagner M., Zacchigna L., Adorno M.,
RA   Martello G., Stinchfield M.J., Soligo S., Morsut L., Inui M., Moro S.,
RA   Modena N., Argenton F., Newfeld S.J., Piccolo S.;
RT   "FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling,
RT   controls Smad4 monoubiquitination.";
RL   Cell 136:123-135(2009).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-763; LYS-769 AND LYS-953, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-862; THR-1102 AND SER-1105,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-862; THR-1102 AND SER-1105,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-862; THR-1051 AND SER-1119,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-515; ARG-535; ARG-577; ARG-591;
RP   ARG-598 AND ARG-604, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [18]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-334; LYS-763; LYS-769; LYS-776;
RP   LYS-793; LYS-953; LYS-1007 AND LYS-1057, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [19]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-776 AND LYS-793, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [20]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-763; LYS-769; LYS-776; LYS-793;
RP   LYS-861; LYS-1057 AND LYS-1118, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [21]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-763; LYS-769; LYS-776; LYS-793
RP   AND LYS-1057, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [22]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-329; LYS-481; LYS-504; LYS-527;
RP   LYS-763; LYS-769; LYS-774; LYS-776; LYS-793; LYS-796; LYS-861; LYS-953;
RP   LYS-1043; LYS-1057 AND LYS-1118, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [23]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-580; SER-696; LYS-811; SER-885; MET-961
RP   AND THR-1090.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Acts as an E3 ubiquitin-protein ligase. Promotes SMAD4
CC       ubiquitination, nuclear exclusion and degradation via the ubiquitin
CC       proteasome pathway. According to PubMed:16751102, does not promote a
CC       decrease in the level of endogenous SMAD4. May act as a transcriptional
CC       repressor. Inhibits the transcriptional response to TGF-beta/BMP
CC       signaling cascade. Plays a role in the control of cell proliferation.
CC       Its association with SMAD2 and SMAD3 stimulates erythroid
CC       differentiation of hematopoietic stem/progenitor (By similarity).
CC       Monoubiquitinates SMAD4 and acts as an inhibitor of SMAD4-dependent
CC       TGF-beta/BMP signaling cascade (Monoubiquitination of SMAD4 hampers its
CC       ability to form a stable complex with activated SMAD2/3 resulting in
CC       inhibition of TGF-beta/BMP signaling cascade). {ECO:0000250,
CC       ECO:0000269|PubMed:10022127, ECO:0000269|PubMed:15820681,
CC       ECO:0000269|PubMed:16751102, ECO:0000269|PubMed:19135894}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27;
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Homooligomer and heterooligomer with TRIM24 and TRIM28 family
CC       members. Interacts with SMAD4 in unstimulated cells. Found in a complex
CC       with SMAD2 and SMAD3 upon addition of TGF-beta. Interacts with SMAD2
CC       and SMAD3. Interacts with SMAD4 under basal and induced conditions and,
CC       upon TGF-beta signaling, with activated SMAD2. Forms a ternary complex
CC       with SMAD4 and SMAD2 upon TGF-beta signaling.
CC       {ECO:0000269|PubMed:10022127, ECO:0000269|PubMed:12096914,
CC       ECO:0000269|PubMed:15820681, ECO:0000269|PubMed:16751102,
CC       ECO:0000269|PubMed:19135894}.
CC   -!- INTERACTION:
CC       Q9UPN9; Q15796: SMAD2; NbExp=6; IntAct=EBI-2214398, EBI-1040141;
CC       Q9UPN9; Q13485: SMAD4; NbExp=6; IntAct=EBI-2214398, EBI-347263;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15820681,
CC       ECO:0000269|PubMed:16751102, ECO:0000269|PubMed:19135894}. Note=In
CC       discrete nuclear dots resembling nuclear bodies. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Alpha;
CC         IsoId=Q9UPN9-1; Sequence=Displayed;
CC       Name=Beta;
CC         IsoId=Q9UPN9-2; Sequence=VSP_005774;
CC   -!- TISSUE SPECIFICITY: Expressed in stem cells at the bottom of the crypts
CC       of the colon (at protein level). Expressed in colon adenomas and
CC       adenocarcinomas (at protein level). Expressed in brain, lung, liver,
CC       spleen, thymus, prostate, kidney, testis, heart, placenta, pancreas,
CC       small intestine, ovary, colon, skeletal muscle and hematopoietic
CC       progenitors.
CC   -!- PTM: Sumoylated with SUMO1. {ECO:0000250|UniProtKB:Q99PP7}.
CC   -!- DISEASE: Note=A chromosomal aberration involving TRIM33 is found in
CC       papillary thyroid carcinomas (PTCs). Translocation t(1;10)(p13;q11)
CC       with RET. The translocation generates the TRIM33/RET (PTC7) oncogene.
CC       {ECO:0000269|PubMed:10439047}.
CC   -!- SIMILARITY: Belongs to the TRIM/RBCC family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD17259.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAA83065.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF119043; AAD17259.1; ALT_FRAME; mRNA.
DR   EMBL; AF220136; AAG53509.1; -; mRNA.
DR   EMBL; AF220137; AAG53510.1; -; mRNA.
DR   EMBL; AB029036; BAA83065.1; ALT_INIT; mRNA.
DR   EMBL; AL035410; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL390241; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AJ132948; CAB55313.1; -; mRNA.
DR   CCDS; CCDS872.1; -. [Q9UPN9-1]
DR   CCDS; CCDS873.1; -. [Q9UPN9-2]
DR   RefSeq; NP_056990.3; NM_015906.3. [Q9UPN9-1]
DR   RefSeq; NP_148980.2; NM_033020.2. [Q9UPN9-2]
DR   PDB; 3U5M; X-ray; 3.08 A; A/B/C/D/E/F/G/H/I/J/K/L=882-1087.
DR   PDB; 3U5N; X-ray; 1.95 A; A/B=882-1087.
DR   PDB; 3U5O; X-ray; 2.70 A; A/B/C/D/E/F/G/H=882-1087.
DR   PDB; 3U5P; X-ray; 2.80 A; A/B/C/D/E/F/G/H=882-1087.
DR   PDB; 5MR8; X-ray; 1.74 A; A=882-1090.
DR   PDBsum; 3U5M; -.
DR   PDBsum; 3U5N; -.
DR   PDBsum; 3U5O; -.
DR   PDBsum; 3U5P; -.
DR   PDBsum; 5MR8; -.
DR   AlphaFoldDB; Q9UPN9; -.
DR   SMR; Q9UPN9; -.
DR   BioGRID; 119625; 240.
DR   CORUM; Q9UPN9; -.
DR   DIP; DIP-54262N; -.
DR   IntAct; Q9UPN9; 86.
DR   MINT; Q9UPN9; -.
DR   STRING; 9606.ENSP00000351250; -.
DR   BindingDB; Q9UPN9; -.
DR   ChEMBL; CHEMBL2176772; -.
DR   GlyGen; Q9UPN9; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9UPN9; -.
DR   PhosphoSitePlus; Q9UPN9; -.
DR   BioMuta; TRIM33; -.
DR   DMDM; 313104270; -.
DR   EPD; Q9UPN9; -.
DR   jPOST; Q9UPN9; -.
DR   MassIVE; Q9UPN9; -.
DR   MaxQB; Q9UPN9; -.
DR   PaxDb; Q9UPN9; -.
DR   PeptideAtlas; Q9UPN9; -.
DR   PRIDE; Q9UPN9; -.
DR   ProteomicsDB; 85392; -. [Q9UPN9-1]
DR   ProteomicsDB; 85393; -. [Q9UPN9-2]
DR   ABCD; Q9UPN9; 1 sequenced antibody.
DR   Antibodypedia; 1303; 438 antibodies from 35 providers.
DR   DNASU; 51592; -.
DR   Ensembl; ENST00000358465.7; ENSP00000351250.2; ENSG00000197323.12. [Q9UPN9-1]
DR   Ensembl; ENST00000369543.6; ENSP00000358556.2; ENSG00000197323.12. [Q9UPN9-2]
DR   GeneID; 51592; -.
DR   KEGG; hsa:51592; -.
DR   MANE-Select; ENST00000358465.7; ENSP00000351250.2; NM_015906.4; NP_056990.3.
DR   UCSC; uc001eew.3; human. [Q9UPN9-1]
DR   CTD; 51592; -.
DR   DisGeNET; 51592; -.
DR   GeneCards; TRIM33; -.
DR   HGNC; HGNC:16290; TRIM33.
DR   HPA; ENSG00000197323; Low tissue specificity.
DR   MalaCards; TRIM33; -.
DR   MIM; 605769; gene.
DR   neXtProt; NX_Q9UPN9; -.
DR   OpenTargets; ENSG00000197323; -.
DR   Orphanet; 146; Differentiated thyroid carcinoma.
DR   PharmGKB; PA38118; -.
DR   VEuPathDB; HostDB:ENSG00000197323; -.
DR   eggNOG; KOG2177; Eukaryota.
DR   GeneTree; ENSGT00940000156361; -.
DR   InParanoid; Q9UPN9; -.
DR   OMA; WCVECEE; -.
DR   OrthoDB; 756911at2759; -.
DR   PhylomeDB; Q9UPN9; -.
DR   TreeFam; TF106455; -.
DR   PathwayCommons; Q9UPN9; -.
DR   Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity.
DR   Reactome; R-HSA-9754189; Germ layer formation at gastrulation.
DR   SignaLink; Q9UPN9; -.
DR   SIGNOR; Q9UPN9; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 51592; 35 hits in 1139 CRISPR screens.
DR   ChiTaRS; TRIM33; human.
DR   GeneWiki; TRIM33; -.
DR   GenomeRNAi; 51592; -.
DR   Pharos; Q9UPN9; Tchem.
DR   PRO; PR:Q9UPN9; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q9UPN9; protein.
DR   Bgee; ENSG00000197323; Expressed in endometrium epithelium and 207 other tissues.
DR   ExpressionAtlas; Q9UPN9; baseline and differential.
DR   Genevisible; Q9UPN9; HS.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0070410; F:co-SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0070412; F:R-SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; TAS:Reactome.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; NAS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; TAS:Reactome.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; IDA:UniProtKB.
DR   Gene3D; 1.20.920.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 2.
DR   IDEAL; IID00505; -.
DR   InterPro; IPR003649; Bbox_C.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR036427; Bromodomain-like_sf.
DR   InterPro; IPR019786; Zinc_finger_PHD-type_CS.
DR   InterPro; IPR027370; Znf-RING_LisH.
DR   InterPro; IPR000315; Znf_B-box.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   Pfam; PF00439; Bromodomain; 1.
DR   Pfam; PF00628; PHD; 1.
DR   Pfam; PF00643; zf-B_box; 1.
DR   Pfam; PF13445; zf-RING_UBOX; 1.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00502; BBC; 1.
DR   SMART; SM00336; BBOX; 2.
DR   SMART; SM00297; BROMO; 1.
DR   SMART; SM00249; PHD; 2.
DR   SMART; SM00184; RING; 2.
DR   SUPFAM; SSF47370; SSF47370; 1.
DR   SUPFAM; SSF57903; SSF57903; 1.
DR   PROSITE; PS50014; BROMODOMAIN_2; 1.
DR   PROSITE; PS50119; ZF_BBOX; 2.
DR   PROSITE; PS01359; ZF_PHD_1; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Bromodomain;
KW   Chromosomal rearrangement; Coiled coil; DNA-binding; Isopeptide bond;
KW   Metal-binding; Methylation; Nucleus; Phosphoprotein; Reference proteome;
KW   Repeat; Repressor; Transcription; Transcription regulation; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..1127
FT                   /note="E3 ubiquitin-protein ligase TRIM33"
FT                   /id="PRO_0000056395"
FT   DOMAIN          974..1046
FT                   /note="Bromo"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00035"
FT   ZN_FING         125..154
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   ZN_FING         212..259
FT                   /note="B box-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   ZN_FING         271..312
FT                   /note="B box-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   ZN_FING         887..934
FT                   /note="PHD-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00146"
FT   REGION          1..147
FT                   /note="Necessary for E3 ubiquitin-protein ligase activity
FT                   and repression of SMAD4 signaling and transcriptional
FT                   repression"
FT   REGION          1..118
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          299..401
FT                   /note="Necessary for oligomerization"
FT   REGION          536..563
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          608..629
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          673..692
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          703..818
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1088..1127
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          299..401
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        100..118
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        703..774
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1106..1127
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         217
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         220
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         241
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         245
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         276
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         279
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         299
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         304
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   SITE            964..965
FT                   /note="Breakpoint for translocation to form TRIM33-RET
FT                   oncogene"
FT   MOD_RES         515
FT                   /note="Asymmetric dimethylarginine; alternate"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         515
FT                   /note="Omega-N-methylarginine; alternate"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         535
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         577
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         591
FT                   /note="Asymmetric dimethylarginine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q99PP7"
FT   MOD_RES         591
FT                   /note="Omega-N-methylarginine; alternate"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         598
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         604
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         763
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         769
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         793
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q99PP7"
FT   MOD_RES         803
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99PP7"
FT   MOD_RES         815
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99PP7"
FT   MOD_RES         862
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         951
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99PP7"
FT   MOD_RES         953
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         1051
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1102
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692"
FT   MOD_RES         1105
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692"
FT   MOD_RES         1119
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   CROSSLNK        329
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        334
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447"
FT   CROSSLNK        481
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        504
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        527
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        763
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        769
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        774
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        776
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        776
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        793
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        793
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        796
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        861
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        953
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1007
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447"
FT   CROSSLNK        1043
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1057
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1118
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1041..1057
FT                   /note="Missing (in isoform Beta)"
FT                   /evidence="ECO:0000303|PubMed:10439047,
FT                   ECO:0000303|PubMed:11331580"
FT                   /id="VSP_005774"
FT   VARIANT         67
FT                   /note="V -> A (in dbSNP:rs6691166)"
FT                   /id="VAR_029494"
FT   VARIANT         580
FT                   /note="M -> I (in a glioblastoma multiforme sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042376"
FT   VARIANT         696
FT                   /note="L -> S (in dbSNP:rs56151583)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042377"
FT   VARIANT         811
FT                   /note="E -> K (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042378"
FT   VARIANT         840
FT                   /note="I -> T (in dbSNP:rs6537825)"
FT                   /evidence="ECO:0000269|PubMed:10022127,
FT                   ECO:0000269|PubMed:10439047, ECO:0000269|PubMed:10470851,
FT                   ECO:0000269|PubMed:11331580"
FT                   /id="VAR_024616"
FT   VARIANT         885
FT                   /note="P -> S (in a glioblastoma multiforme sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042379"
FT   VARIANT         961
FT                   /note="V -> M (in dbSNP:rs55688622)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042380"
FT   VARIANT         1090
FT                   /note="P -> T (in dbSNP:rs55784699)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042381"
FT   MUTAGEN         125
FT                   /note="C->A: Abolishes E3 activity but does not affect
FT                   interaction with SMAD4; when associated with A-128."
FT                   /evidence="ECO:0000269|PubMed:15820681"
FT   MUTAGEN         128
FT                   /note="C->A: Abolishes E3 activity but does not affect
FT                   interaction with SMAD4; when associated with A-125."
FT                   /evidence="ECO:0000269|PubMed:15820681"
FT   CONFLICT        89
FT                   /note="V -> E (in Ref. 5; CAB55313)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        451..453
FT                   /note="PAA -> LLH (in Ref. 5; CAB55313)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        909
FT                   /note="F -> S (in Ref. 5; CAB55313)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1037
FT                   /note="R -> T (in Ref. 1; AAD17259)"
FT                   /evidence="ECO:0000305"
FT   STRAND          888..890
FT                   /evidence="ECO:0007829|PDB:3U5N"
FT   TURN            891..893
FT                   /evidence="ECO:0007829|PDB:5MR8"
FT   STRAND          897..901
FT                   /evidence="ECO:0007829|PDB:5MR8"
FT   STRAND          903..906
FT                   /evidence="ECO:0007829|PDB:5MR8"
FT   TURN            911..913
FT                   /evidence="ECO:0007829|PDB:5MR8"
FT   STRAND          914..916
FT                   /evidence="ECO:0007829|PDB:5MR8"
FT   STRAND          918..920
FT                   /evidence="ECO:0007829|PDB:3U5P"
FT   TURN            929..931
FT                   /evidence="ECO:0007829|PDB:5MR8"
FT   STRAND          934..936
FT                   /evidence="ECO:0007829|PDB:5MR8"
FT   HELIX           944..949
FT                   /evidence="ECO:0007829|PDB:5MR8"
FT   TURN            950..952
FT                   /evidence="ECO:0007829|PDB:5MR8"
FT   HELIX           960..974
FT                   /evidence="ECO:0007829|PDB:5MR8"
FT   HELIX           980..982
FT                   /evidence="ECO:0007829|PDB:5MR8"
FT   HELIX           993..996
FT                   /evidence="ECO:0007829|PDB:5MR8"
FT   HELIX           1003..1009
FT                   /evidence="ECO:0007829|PDB:5MR8"
FT   STRAND          1011..1013
FT                   /evidence="ECO:0007829|PDB:3U5O"
FT   HELIX           1021..1038
FT                   /evidence="ECO:0007829|PDB:5MR8"
FT   HELIX           1061..1080
FT                   /evidence="ECO:0007829|PDB:5MR8"
FT   STRAND          1081..1083
FT                   /evidence="ECO:0007829|PDB:3U5O"
SQ   SEQUENCE   1127 AA;  122533 MW;  7A36013799E9933C CRC64;
     MAENKGGGEA ESGGGGSGSA PVTAGAAGPA AQEAEPPLTA VLVEEEEEEG GRAGAEGGAA
     GPDDGGVAAA SSGSAQAASS PAASVGTGVA GGAVSTPAPA PASAPAPGPS AGPPPGPPAS
     LLDTCAVCQQ SLQSRREAEP KLLPCLHSFC LRCLPEPERQ LSVPIPGGSN GDIQQVGVIR
     CPVCRQECRQ IDLVDNYFVK DTSEAPSSSD EKSEQVCTSC EDNASAVGFC VECGEWLCKT
     CIEAHQRVKF TKDHLIRKKE DVSESVGASG QRPVFCPVHK QEQLKLFCET CDRLTCRDCQ
     LLEHKEHRYQ FLEEAFQNQK GAIENLLAKL LEKKNYVHFA ATQVQNRIKE VNETNKRVEQ
     EIKVAIFTLI NEINKKGKSL LQQLENVTKE RQMKLLQQQN DITGLSRQVK HVMNFTNWAI
     ASGSSTALLY SKRLITFQLR HILKARCDPV PAANGAIRFH CDPTFWAKNV VNLGNLVIES
     KPAPGYTPNV VVGQVPPGTN HISKTPGQIN LAQLRLQHMQ QQVYAQKHQQ LQQMRMQQPP
     APVPTTTTTT QQHPRQAAPQ MLQQQPPRLI SVQTMQRGNM NCGAFQAHQM RLAQNAARIP
     GIPRHSGPQY SMMQPHLQRQ HSNPGHAGPF PVVSVHNTTI NPTSPTTATM ANANRGPTSP
     SVTAIELIPS VTNPENLPSL PDIPPIQLED AGSSSLDNLL SRYISGSHLP PQPTSTMNPS
     PGPSALSPGS SGLSNSHTPV RPPSTSSTGS RGSCGSSGRT AEKTSLSFKS DQVKVKQEPG
     TEDEICSFSG GVKQEKTEDG RRSACMLSSP ESSLTPPLST NLHLESELDA LASLENHVKI
     EPADMNESCK QSGLSSLVNG KSPIRSLMHR SARIGGDGNN KDDDPNEDWC AVCQNGGDLL
     CCEKCPKVFH LTCHVPTLLS FPSGDWICTF CRDIGKPEVE YDCDNLQHSK KGKTAQGLSP
     VDQRKCERLL LYLYCHELSI EFQEPVPASI PNYYKIIKKP MDLSTVKKKL QKKHSQHYQI
     PDDFVADVRL IFKNCERFNE MMKVVQVYAD TQEINLKADS EVAQAGKAVA LYFEDKLTEI
     YSDRTFAPLP EFEQEEDDGE VTEDSDEDFI QPRRKRLKSD ERPVHIK
//
